Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Paclitaxel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 0.97 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 0.97 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 0.97 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 0.97 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 0.97 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 0.97 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 0.97 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 0.97 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 0.97 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 0.97 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 0.97 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 0.97 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 0.97 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 0.97 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 3/20 | 0.97 |
| ▸ | NPC1 | O15118 | 8/20 | 0.97 |
| ▸ | RAB9A | P51151 | 7/20 | 0.97 |
| ▸ | USP2 | O75604 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paclitaxel SCHEMBL5151579 | 0.98 | NPC1 (0.98) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL18389589 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL10122072 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL19996646 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760447 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760443 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL13622863 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL759366 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL22149786 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL12929005 | 0.98 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129014-B1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | TETRAHEDRON (FR) | 2021-05-12 | — | — | EP | claimed |
| US-10308602-B2 | Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents | TETRAHEDRON (FR) | 2019-06-04 | — | — | US | claimed |
| US-20170114011-A1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS ANTITUMOR AGENTS | TETRAHEDRON (FR) | 2017-04-27 | — | — | US | claimed |
| EP-3129014-A2 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF AS ANTITUMOUR AGENTS | Tetrahedron (FR) | 2017-02-15 | — | — | EP | claimed |
| US-9345677-B2 | Compositions, methods and kits relating to HER-2 cleavage | INCYTE CORPORATION (US) | 2016-05-24 | — | — | US | claimed |
| US-20120263676-A1 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-10-18 | — | — | US | claimed |
| EP-1613269-A2 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | Incyte Corporation (US) | 2006-01-11 | — | — | EP | claimed |
| US-20040247602-A1 | Compositions, methods and kits relating to Her-2 cleavage | INCYTE CORPORATION | 2004-12-09 | — | — | US | claimed |
| WO-2004089294-A2 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORPORATION (US) | 2004-10-21 | — | — | WO | claimed |
| US-6537988-B2 | Imidazole-1h-1,4-benzodiazepine derivatives along with antiproliferative cytotoxic and cytostatic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-25 | — | — | US | claimed |
| EP-1272193-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Bristol-Myers Squibb Company (US) | 2003-01-08 | — | — | EP | claimed |
| US-6458835-B2 | USING 4-(((CYANOIMINO)-((1,2,2-TRIMETHYLPROPYL)AMINO) METHYL)AMINO)BENZONITRILE | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-01 | — | — | US | claimed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | claimed |
| WO-2001072721-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-04 | — | — | WO | claimed |
| US-20010020038-A1 | Method for inhibiting or treating chemotherapy-induced hair loss | BRISTOL-MYERS SQUIBB COMPANY | 2001-09-06 | — | — | US | claimed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| CN-114805352-B | Pyrrolopyridine substituted fused quinoline compounds as PI3K/MTOR inhibitors | 南京爱德程医药科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-0626953-A4 | NOVEL SIDECHAIN-BEARING TAXANES AND INTERMEDIATES THEREOF. | BRISTOL MYERS SQUIBB CO (US) | 1995-05-03 | — | — | EP | disclosed |
| EP-0626953-A1 | NOVEL SIDECHAIN-BEARING TAXANES AND INTERMEDIATES THEREOF | Bristol-Myers Squibb Company (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994014787-A1 | NOVEL SIDECHAIN-BEARING TAXANES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020038-A1 | Method for inhibiting or treating chemotherapy-induced hair loss | MGMT, TUBB2B, CCAR2 | TUBB4A 39/4885TUBB 9/4885TUBA3C 610/4885 |
| US-20170114011-A1 | NOVEL ORGANOSELENIUM COMPOUNDS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS ANTITUMOR AGENTS | SCLY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC7A5 | TUBB4A 1301/4885TUBB 1983/4885TUBA3C 1068/4885 |
| US-10308602-B2 | Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents | SCLY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT5 | TUBB4A 1516/4885TUBB 2083/4885TUBA3C 1322/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | TUBB4A 2071/4885TUBB 1486/4885TUBA3C 2452/4885 |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | ABCB11, TP53, SLC10A1 | TUBB4A 521/4885TUBB 692/4885TUBA3C 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.